Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 304Carcinoma, Non-Small-Cell Lung 182Ovarian Neoplasms 154Lung Neoplasms 92Esophageal Neoplasms 75Triple Negative Breast Neoplasms 71Stomach Neoplasms 71Fallopian Tube Neoplasms 68Squamous Cell Carcinoma of Head and Neck 51Esophageal Squamous Cell Carcinoma 50Neoplasm Metastasis 48Neoplasms 45Endometrial Neoplasms 42Head and Neck Neoplasms 41Carcinoma, Ovarian Epithelial 41Uterine Cervical Neoplasms 37Recurrence 26Carcinoma, Squamous Cell 23Adenocarcinoma Of Esophagus 22Urinary Bladder Neoplasms 19Melanoma 19Inflammatory Breast Neoplasms 19Prostatic Neoplasms 18Adenocarcinoma of Lung 17Carcinoma 15Breast Neoplasms, Male 15Unspecified Adult Solid Tumor, Protocol Specific 14Testicular Neoplasms 13Small Cell Lung Carcinoma 12Peritoneal Neoplasms 12

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Primary Breast Cancer × Paclitaxel × Clear all
NCT01019616 2021-11-29

Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

Peking University

Phase 3 Unknown
400 enrolled
Breast

Primary Breast Cancer

NCT04127019 2020-02-26

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Fudan University

Phase 3 Completed
2,079 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡